UA71554C2 - Agonists of apolipoprotein a-i and their use for treatment of disorders associated with dyslipidemia - Google Patents

Agonists of apolipoprotein a-i and their use for treatment of disorders associated with dyslipidemia Download PDF

Info

Publication number
UA71554C2
UA71554C2 UA2000042498A UA2000042498A UA71554C2 UA 71554 C2 UA71554 C2 UA 71554C2 UA 2000042498 A UA2000042498 A UA 2000042498A UA 2000042498 A UA2000042498 A UA 2000042498A UA 71554 C2 UA71554 C2 UA 71554C2
Authority
UA
Ukraine
Prior art keywords
peptide
agonist
apoa
represented
amino acid
Prior art date
Application number
UA2000042498A
Other languages
English (en)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UA71554C2 publication Critical patent/UA71554C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
UA2000042498A 1997-09-29 1998-09-28 Agonists of apolipoprotein a-i and their use for treatment of disorders associated with dyslipidemia UA71554C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/940,093 US6037323A (en) 1997-09-29 1997-09-29 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
PCT/US1998/020328 WO1999016408A2 (fr) 1997-09-29 1998-09-28 Agonistes d'apolipoproteine a-i et leur utilisation pour traiter des troubles de la dyslipidemie

Publications (1)

Publication Number Publication Date
UA71554C2 true UA71554C2 (en) 2004-12-15

Family

ID=25474213

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2000042498A UA71554C2 (en) 1997-09-29 1998-09-28 Agonists of apolipoprotein a-i and their use for treatment of disorders associated with dyslipidemia

Country Status (19)

Country Link
US (5) US6037323A (fr)
EP (1) EP1019010B1 (fr)
JP (1) JP2003525840A (fr)
KR (1) KR100650974B1 (fr)
CN (1) CN1345245A (fr)
AT (1) ATE363287T1 (fr)
AU (1) AU747823B2 (fr)
CA (1) CA2304931A1 (fr)
DE (1) DE69837855T2 (fr)
ES (1) ES2288768T3 (fr)
HK (1) HK1044898A1 (fr)
HU (1) HUP0003280A3 (fr)
IL (1) IL135321A0 (fr)
NO (1) NO20001600L (fr)
NZ (1) NZ503719A (fr)
PL (1) PL200744B1 (fr)
RU (1) RU2219941C2 (fr)
UA (1) UA71554C2 (fr)
WO (1) WO1999016408A2 (fr)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
IL145712A0 (en) 1999-04-01 2002-07-25 Esperion Therapeutics Inc Ether compounds, compositions, and uses thereof
US7407662B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US20090017069A1 (en) * 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US7407663B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US7439052B2 (en) * 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
AU2007237157B2 (en) * 2000-08-24 2009-04-09 The Regents Of The University Of California Peptides that ameliorate atherosclerosis
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
DE10051983A1 (de) * 2000-10-20 2002-06-13 Beate Kehrel Inhibierung der pathogenen Wirkung oxidierter Proteine
EP1353666B1 (fr) * 2001-01-02 2013-07-03 The Cleveland Clinic Foundation La myeloperoxydase, un indicateur de risque des maladies cardio-vasculaires
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US7217785B2 (en) * 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
US7033500B2 (en) * 2001-06-25 2006-04-25 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
US6991727B2 (en) * 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US20060060520A1 (en) * 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
US20030127386A1 (en) * 2001-06-25 2003-07-10 Bomberger David C. Hollow fiber contactor systems for removal of lipids from fluids
WO2003000373A1 (fr) * 2001-06-25 2003-01-03 Lipid Sciences, Inc. Systemes et procedes d'elimination de lipides contenus dans des fluides a l'aide d'un solvant
WO2003026588A2 (fr) * 2001-09-28 2003-04-03 Esperion Therapeutics, Inc. Methodes et appareils d'extrusion de vesicules a haute pression
MXPA04002848A (es) * 2001-09-28 2005-06-06 Esperion Therapeutics Inc Prevencion y tratamiento de restenosis por administracion local de medicamento.
US20040009216A1 (en) * 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
US7691965B2 (en) * 2002-05-08 2010-04-06 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US20100204103A1 (en) * 2002-05-08 2010-08-12 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US20040067873A1 (en) * 2002-05-17 2004-04-08 Dasseux Jean-Louis H. Method of treating dyslipidemic disorders
NZ537006A (en) * 2002-05-17 2008-01-31 Esperion Therapeutics Inc The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ
JP2006508045A (ja) * 2002-07-30 2006-03-09 エスペリオン セラピューティクス，インコーポレイテッド ヒト以外の動物のアポリポプロテインａ−ｉタンパク質の使用方法
AU2003268190B2 (en) * 2002-08-26 2008-04-03 Eli Lilly And Company Treating Alzheimers using delipidated protein particles
CA2513660C (fr) * 2003-01-23 2012-05-08 Esperion Therapeutics, Inc. Composes hydroxyles et compositions de regulation du cholesterol et utilisations associees
US20060166891A1 (en) * 2003-04-22 2006-07-27 Sircar Jagadish C Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
JP2007527387A (ja) * 2003-07-03 2007-09-27 リピッド サイエンシーズ，インコーポレイテッド 脂質含量の低下したｈｄｌの粒子誘導体を製造するための方法及び装置
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US7459286B1 (en) 2003-10-22 2008-12-02 The Cleveland Clinic Foundation Assessing the risk of a major adverse cardiac event in patients with chest pain
US6960803B2 (en) * 2003-10-23 2005-11-01 Silicon Storage Technology, Inc. Landing pad for use as a contact to a conductive spacer
ATE546734T1 (de) * 2003-12-05 2012-03-15 Cleveland Clinic Foundation Risikomarker für eine herzkreislaufkrankheit
EP1699527A1 (fr) * 2004-01-02 2006-09-13 Advanced Cardiovascular Systems, Inc. Dispositifs medicaux revetus de lipoproteine a haute densite
JP2007531537A (ja) * 2004-04-06 2007-11-08 セダーズ−シナイ　メディカル　センター アポリポタンパク質ａ−ｉおよびアポリポタンパク質ａ−ｉｍｉｌａｎｏをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
WO2006020498A2 (fr) * 2004-08-11 2006-02-23 The Cleveland Clinic Foundation Agents therapeutiques et procedes associes pour maladies cardiovasculaires
RU2448977C2 (ru) * 2004-09-16 2012-04-27 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Обладающий способностью облегчать по меньшей мере один симптом воспалительного состояния пептид, содержащая его фармацевтическая композиция и способ лечения атеросклероза с их помощью
WO2006049597A1 (fr) * 2004-10-27 2006-05-11 Avanir Pharmaceuticals Composes derives d'acides amines utilises en tant que modulateurs du transport inverse du cholesterol
US7579319B2 (en) 2004-12-06 2009-08-25 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US20060160721A1 (en) * 2004-12-22 2006-07-20 Baylor College Of Medicine Method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
US7759315B2 (en) 2005-03-09 2010-07-20 Csl Behring Ag Treatment of inflammatory conditions of the intestine
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EP1890715A4 (fr) 2005-04-29 2009-10-28 Univ California Peptides et mimetiques de peptides destines a traiter les pathologies caracterisees par une reaction inflammatoire
EP1924262B1 (fr) 2005-08-22 2011-11-16 Melior Pharmaceuticals I, Inc. Procedes et preparations pour moduler une activite de kinase lyn et traiter les troubles y relatifs
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
US8163699B2 (en) * 2006-06-01 2012-04-24 Montreal Heart Institute Method for the treatment of valvular disease
WO2007149355A2 (fr) * 2006-06-16 2007-12-27 Lipid Sciences, Inc. Nouveaux peptides qui favorisent un écoulement de lipides
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
WO2008021088A2 (fr) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Les salicylanilides renforcent l'administration par voie orale de peptides thérapeutiques
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US8541236B2 (en) * 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
WO2008094905A2 (fr) * 2007-01-29 2008-08-07 Lipid Sciences, Inc. Peptides mimétiques de hdl encapsulés
MX2009008135A (es) * 2007-01-31 2009-08-12 Nutrition 21 Inc Uso de histidinato de cromo para tratamiento de alteraciones cardiometabolicas.
JP2010518860A (ja) * 2007-02-20 2010-06-03 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド Ｌｙｎキナーゼの活性化剤の同定方法
ES2386905T3 (es) 2007-03-01 2012-09-05 Csl Limited Tratamiento de disfunción endotelial en pacientes diabéticos
WO2008112706A1 (fr) 2007-03-13 2008-09-18 Nutrition 21, Inc. Procédés et compositions utilisés pour la libération prolongée de chrome
WO2009002867A2 (fr) 2007-06-26 2008-12-31 Nutrition 21, Inc. Forme posologique à unités multiples contenant un agent thérapeutique en combinaison avec un complément alimentaire
CA2693809A1 (fr) * 2007-07-23 2009-01-29 Melior Discovery, Inc. Procedes d'activation de irs-1 et akt
EP2195331B1 (fr) 2007-08-28 2013-11-20 Uab Research Foundation Polypeptides de synthèse imitant l'apolipoprotéine e et leurs procédés d'utilisation
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
EP4241767B1 (fr) 2008-11-10 2024-10-23 Arbutus Biopharma Corporation Nouveaux lipides et compositions d'administration d'agents thérapeutiques
US20120101148A1 (en) 2009-01-29 2012-04-26 Alnylam Pharmaceuticals, Inc. lipid formulation
AU2010213568B2 (en) 2009-02-16 2014-11-20 Cerenis Therapeutics Holding Sa Apolipoprotein A-I Mimics
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
SG176553A1 (en) 2009-05-05 2012-01-30 Muthiah Manoharan Lipid compositions
TR201811076T4 (tr) 2009-06-10 2018-08-27 Arbutus Biopharma Corp Geliştirilmiş lipit formulasyonu.
EP2464336A4 (fr) 2009-08-14 2013-11-20 Alnylam Pharmaceuticals Inc Compositions formulées dans des lipides et procédés pour inhiber l' expression d'un gène du virus ebola
WO2011040654A1 (fr) * 2009-09-30 2011-04-07 서울대학교산학협력단 Peptides mimétiques d'apolipoprotéine a-1, et agent thérapeutique pour traiter l'hyperlipidémie et maladies associées à l'hyperlipidémie comprenant ceux-ci
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
WO2011071860A2 (fr) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions utilisées pour l'administration d'acides nucléiques
EP3494963A1 (fr) 2009-12-18 2019-06-12 The University of British Columbia Procédés et compositions d'administration d'acides nucléiques
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (fr) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Variants d'apolipoprotéine a1 résistants à l'oxydation dimères
US20130158055A1 (en) 2010-05-28 2013-06-20 Andrew G. Reaume Prevention Of Pancreatic Beta Cell Degeneration
CA2800401C (fr) 2010-06-03 2020-09-15 Alnylam Pharmaceuticals, Inc. Lipides biodegradables pour l'administration de principes actifs
US20130323269A1 (en) 2010-07-30 2013-12-05 Muthiah Manoharan Methods and compositions for delivery of active agents
WO2012016188A2 (fr) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour l'administration d'agents actifs
JP2013544488A (ja) 2010-08-30 2013-12-19 エフ．ホフマン−ラ ロシュ アーゲー テトラネクチン−アポリポタンパク質ａ−ｉ脂質粒子を産生するための方法、脂質粒子自体、及びその使用
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
JP5902197B2 (ja) 2011-01-11 2016-04-13 アルニラム・ファーマシューティカルズ・インコーポレーテッド Ｐｅｇ化脂質および薬剤送達のためのそれらの使用
PT2673296T (pt) 2011-02-07 2019-01-31 Cerenis Therapeutics Holding Sa Complexos de lipoproteínas e sua fabricação e utilização
ES2927800T3 (es) 2011-03-01 2022-11-11 Nutrition 21 Llc Composición de insulina y cromo para el tratamiento y la prevención de diabetes, hipoglicemia y trastornos relacionados
EP2760477B1 (fr) 2011-09-27 2018-08-08 Alnylam Pharmaceuticals, Inc. Lipides di-aliphatiques pegylés substitués
SG11201403207WA (en) 2011-12-12 2014-09-26 Melior Pharmaceuticals I Inc Treatment of type i and type ii diabetes
CN103073646A (zh) * 2012-03-13 2013-05-01 华中科技大学 一种运载蜂毒肽的多肽、运载蜂毒肽的纳米颗粒及其应用
CA2902209C (fr) 2013-03-15 2025-02-04 The Regents Of The University Of California Peptides à toxicité réduite stimulant un écoulement de cholestérol
EP2853259A1 (fr) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Composition de lipoprotéines haute densité reconstituées et leurs utilisations
KR20170003611A (ko) 2014-05-02 2017-01-09 세레니스 쎄라퓨틱스 홀딩 에스에이 Ｈｄｌ 요법 마커
US10220046B2 (en) 2014-07-14 2019-03-05 The Regents Of The University Of Michigan Compositions and methods for disease treatment using nanoparticle delivered compounds
CA2954475C (fr) 2014-07-31 2023-05-16 Uab Research Foundation Peptides e-mimetiques d'apo ayant une puissance superieure afin de degager le taux de cholesterol plasmatique
US10307491B2 (en) 2015-01-30 2019-06-04 The Regents Of The University Of Michigan Liposomal particles comprising biological molecules and uses thereof
CN107530307A (zh) 2015-03-13 2018-01-02 艾斯柏伦治疗公司 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CA2979712C (fr) * 2015-03-25 2024-01-23 The Regents Of The University Of Michigan Compositions nanoparticulaires servant a distribuer des biomacromolecules
GB2564295A (en) 2016-02-11 2019-01-09 Nutrition 21 Llc Chromium containing compositions for improving health and fitness
WO2017223085A2 (fr) 2016-06-20 2017-12-28 The Regents Of The University Of Michigan Compositions et méthodes pour administrer des agents biomacromoléculaires
AU2018250795B2 (en) 2017-04-10 2022-02-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Treatment of adipocytes
WO2019030574A1 (fr) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Cargomères
WO2019104237A1 (fr) 2017-11-22 2019-05-31 Hdl Therapeutics, Inc. Systèmes et procédés pour amorcer des circuits fluides d'un système de traitement de plasma
EP3731814A4 (fr) 2017-12-28 2021-09-29 HDL Therapeutics, Inc. Procédés de conservation et d'administration de pré-bêta lipoprotéines de haute densité extraites à partir de plasma humain
EP4438114A3 (fr) 2019-06-21 2024-12-25 Esperion Therapeutics, Inc. Procédés de fabrication d'acide bempédoïque et compositions associées
IL297336A (en) 2020-04-16 2022-12-01 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
KR20230079132A (ko) 2020-10-01 2023-06-05 아비오닉스 파마 에스에이 안질환을 치료하는 데 사용하기 위한 지질 결합 단백질-기반 복합체를 포함하는 조성물
EP4228797A4 (fr) * 2020-10-16 2024-10-16 Cedars-Sinai Medical Center Système et méthodes de collecte d'échantillons gazeux dérivés du microbiome
AU2022258815A1 (en) 2021-04-15 2023-10-19 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
KR20240167701A (ko) 2022-04-06 2024-11-27 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 안질환을 치료하는 방법
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
US20250352613A1 (en) 2022-06-10 2025-11-20 Stanislas FAGUER Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
EP4536269A2 (fr) 2022-06-10 2025-04-16 Abionyx Pharma SA Méthodes de traitement d'affections aiguës à l'aide de complexes à base de protéines se liant à des lipides
KR20260010675A (ko) 2023-01-13 2026-01-21 아비오닉스 파마 에스에이 지질 결합 단백질 분자 치료
WO2025093929A1 (fr) 2023-10-31 2025-05-08 Abionyx Pharma Sa Thérapie par molécules à protéine d'ancrage lipidique

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (fr) * 1977-08-05 1981-02-13 Battelle Memorial Institute
CA1173360A (fr) * 1979-06-22 1984-08-28 Jurg Schrank Produits pharmaceutiques
DE3241102A1 (de) * 1982-11-06 1984-05-10 A. Nattermann & Cie GmbH, 5000 Köln Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
US4643988A (en) * 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US5204328A (en) * 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
DK53291D0 (da) * 1991-03-25 1991-03-25 Carlbiotech Ltd As Smaa peptider og peptidrelaterede stoffer samt farmaceutiske praeparater indeholdende saadanne forbindelser
US5527790A (en) * 1991-09-30 1996-06-18 The University Of British Columbia Bis(maltolato)oxovanadium compositions for the treatment of elevated blood sugar
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
JPH07507554A (ja) * 1992-06-12 1995-08-24 エヌ・ブイ・イノゲネテイクス・エス・エイ 新規ペプチドおよびタンパク質，それらの調製方法，ならびにコレステロール受容体としてのそれらの使用
US5674855A (en) * 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
US5470753A (en) * 1992-09-03 1995-11-28 Selectide Corporation Peptide sequencing using mass spectrometry
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
FR2723741A1 (fr) * 1994-08-16 1996-02-23 Fournier Sca Lab Peptides inhibiteurs de la proteine de transfert des esters de cholesterol et leur utilisation en therapeutique
US5545661A (en) * 1995-05-16 1996-08-13 Eli Lilly And Company Methods for inhibiting bone loss with bis-pyrone oxovanadium compounds
FR2734568B1 (fr) * 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
WO1997036927A1 (fr) * 1996-03-29 1997-10-09 Dario Boffelli Molecules amphipathiques agissant comme inhibiteurs de l'absorption du cholesterol et d'autres lipides
RU2101287C1 (ru) * 1996-04-16 1998-01-10 Научно-исследовательский институт биомедицинской химии РАМН Оксованадиевые комплексы l-яблочной кислоты, проявляющие гипогликемическую активность
GB9609702D0 (en) * 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

Also Published As

Publication number Publication date
NO20001600D0 (no) 2000-03-28
IL135321A0 (en) 2001-05-20
US20080058270A1 (en) 2008-03-06
CN1345245A (zh) 2002-04-17
US6734169B2 (en) 2004-05-11
EP1019010B1 (fr) 2007-05-30
PL200744B1 (pl) 2009-01-30
ES2288768T3 (es) 2008-01-16
KR100650974B1 (ko) 2006-11-29
HUP0003280A1 (hu) 2001-01-29
US20030008827A1 (en) 2003-01-09
CA2304931A1 (fr) 1999-04-08
HK1044898A1 (zh) 2002-11-08
DE69837855D1 (de) 2007-07-12
NZ503719A (en) 2002-09-27
KR20010030805A (ko) 2001-04-16
NO20001600L (no) 2000-05-03
JP2003525840A (ja) 2003-09-02
US20040198662A1 (en) 2004-10-07
AU9779198A (en) 1999-04-23
EP1019010A1 (fr) 2000-07-19
US7211565B2 (en) 2007-05-01
US6037323A (en) 2000-03-14
DE69837855T2 (de) 2008-02-07
PL362598A1 (en) 2004-11-02
AU747823B2 (en) 2002-05-23
HUP0003280A3 (en) 2005-06-28
WO1999016408A2 (fr) 1999-04-08
EP1019010A4 (fr) 2003-07-23
RU2219941C2 (ru) 2003-12-27
US6265377B1 (en) 2001-07-24
ATE363287T1 (de) 2007-06-15
US20040029807A9 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
UA71553C2 (uk) АГОНІСТ АПОЛІПОПРОТЕЇНУ А-І (ApoA-I), МУЛЬТИМІРНИЙ ApoA-I (ВАРІАНТИ), КОМПЛЕКС АГОНІСТА ApoA-I І ЛІПІДУ ТА СПОСІБ ЛІКУВАННЯ ДИСЛІПІДЕМІЧНИХ ПОРУШЕНЬ
UA71552C2 (uk) Агоніст аполіпопротеїну а-і (аро а-і), мультимірний аро а-і (варіанти) та їх застосування в лікуванні дисліпідемічних порушень
ES2288768T3 (es) Apolipoproteina a-i agonista y su uso para el tratamiento de desordenes dislipidemicos.
JP5719783B2 (ja) アポリポタンパクａ−ｉ模倣物
JP2007534612A (ja) 高コレステロール血症の治療のためのコレステロール逆輸送メディエータ
MXPA00003049A (en) Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders
MXPA00003054A (en) Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders
MXPA00003055A (en) Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders